Core Viewpoint - The announcement indicates that the drug JMT206, a fully humanized monoclonal antibody targeting Act RIIA/IIB, has received approval from the National Medical Products Administration of China to conduct clinical trials, highlighting its potential in obesity management and muscle preservation [1] Group 1: Product Details - JMT206 specifically binds to ActRIIA and ActRIIB, blocking the interaction of Activin A, GDF8, and GDF11 with Act RII, thereby inhibiting downstream signaling pathways [1] - The drug aims to reduce muscle loss and promote skeletal muscle maintenance and growth, achieving a dual effect of muscle gain and fat loss [1] - It also assists GLP-1 receptor agonists in achieving higher quality weight loss outcomes [1] Group 2: Clinical Application - The approved clinical indication for JMT206 is weight management in individuals who are obese or overweight with at least one weight-related comorbidity [1] - Preclinical studies have demonstrated high bioavailability, good efficacy, and safety, indicating significant clinical development value [1]
石药集团：重组全人源抗Act RIIA / IIB单克隆抗体药物(JMT206)在中国获临床试验批准